Nanoalum adjuvanted vaccines: small details make a big difference

• Published in: Seminars in immunology 2021-08, Vol.56, p.101544-101544, Article 101544
• Main Authors: Raponi, Arianna, Brewer, James M., Garside, Paul, Laera, Donatello
• Format: Article
• Language: English
• Subjects: Adjuvants; Adjuvants, Immunologic - pharmacology; Adsorption; Aluminium salts; Aluminum; Humans; Nanoalum; Nanoparticles; Vaccines
• ISSN: 1044-5323; 1096-3618
• DOI: 10.1016/j.smim.2021.101544

•Modelling Aluminium salt formulations to the desired type of vaccine immune response.•Reducing the size of Aluminium particles to obtain more effective adjuvants.•Faster migration into the lymph nodes and less inflammation at the injection site. Purified vaccine antigens offer important safety and reactogenicity advantages compared with live attenuated or whole killed virus and bacterial vaccines. However, they require the addition of adjuvants to induce the magnitude, duration and quality of immune response required to achieve protective immunity. Aluminium salts have been used as adjuvants in vaccines for almost a century. In the literature, they are often referred to as aluminium-based adjuvants (ABAs), or aluminium salt-containing adjuvants or more simply “alum”. All these terms are used to group aluminium suspensions that are very different in terms of atomic composition, size, and shape. They differ also in stability, antigen-adsorption, and antigen-release kinetics. Critically, these parameters also have a profound effect on the character and magnitude of the immune response elicited. Recent findings suggest that, by reducing the size of aluminium from micro to nanometers, a more effective adjuvant is obtained, together with the ability to sterile filter the vaccine product. However, the behaviour of aluminium nanoparticles in vaccine formulations is different from microparticles, requiring specific formulation strategies, as well as a more detailed understanding of how formulation influences the immune response generated. Here we review the current state of art of aluminium nanoparticles as adjuvants, with a focus on their immunobiology, preparation methods, formulation optimisation and stabilisation.